Skip to main content
Premium Trial:

Request an Annual Quote

Broad Institute Taps Convey's Hybrid-Core System for Genomic Research


Convey Computer said this week that the Broad Institute has purchased one of its hybrid core computing systems, which will be used to speed up portions of its next-generation sequencing data analysis pipeline.

Specifically, the Broad will use an accelerated version of the Burrows-Wheeler aligner that is implemented on Convey's HC-2 system.

Convey developed and implemented a version of BWA on its platform two years ago that it claimed increased genome reference mapping rates by a factor of 15 compared to commodity servers (BI 10/14/2011).

"With the Convey system, we expect to increase performance of BWA tenfold," Tim Fennell, the informatics director for the Broad's Genomics Platform, said in statement.

Convey’s hybrid-core architecture pairs classic Intel x86 microprocessors with a coprocessor comprised of field-programmable gate arrays.

Customers of the company's platform include the UK's Genome Analysis Center (BI 2/1/2013) and the Jackson Laboratory (BI 4/27/2012). Convey also partners with CLC Bio to provide a combined software and hardware solution for NGS data analysis (BI 4/20/2012).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.